% | $
Quotes you view appear here for quick access.

Cadence Pharmaceuticals, AŞ Message Board

  • laonda32 laonda32 Mar 11, 2013 4:00 PM Flag

    Detailed CADX analysis

    on SmithsOnStocks. Please google cadence-potential-near-term-catalyst-for-the-stock.............

    Cadence: Potential Near Term Catalyst for the Stock
    Investment Thesis

    I continue with my buy recommendation on CADX. I believe that there is a high probability for an important near term catalyst that could give the stock a nice boost. This would be a legal settlement with Exela Pharmaceuticals, which is challenging Ofirmev’s patents. If it is similar to a settlement reached with the other generic challenger Perrigo (PRGO), it could extend the period of exclusivity until 2019 or longer. The case is scheduled for trial in May, 2013 and it is likely that we will hear of the settlement before then. If I am wrong and Exela chooses to go to trial, I think that there is an excellent chance that Cadence ultimately wins the lawsuit. However, Exela’s choosing to go to trial could cause modest price weakness.
    Cadence introduced its first and only product, the hospital analgesic Ofirmev (intravenous acetaminophen), in January 2011 when the stock was trading at about $7.00. The price climbed steadily and reached about $9.00 in mid-2011. Then sentiment began to shift sharply negative. The sales ramp for Ofirmev was slower than expected leading to downward revisions in sales projections and in June, 2011, Ofirmev’s patents were challenged by two generic drug companies: Exela Pharmaceuticals and Perrigo................

    Sentiment: Buy